Skip to Main Content

Paper Details

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer.
J Clin Oncol
17
2023
BRAF, Binimetinib, Encorafenib, MEK, Metastatic Non-Small-Cell Lung Cancer, NSCLC, Patients, TRAE, binimetinib, diarrhea, encorafenib, fatigue, intracranial hemorrhage, melanoma, metastatic NSCLC, metastatic melanoma, metastatic non-small-cell lung cancer, nausea, patients
Author NameAffiliation
Gregory J RielyMemorial Sloan Kettering Cancer Center
Jonathan W GoldmanDavid Geffen School of Medicine at university of california los angeles
Jonathan W GoldmanDavid Geffen School of Medicine at university of california los angeles
Daniel MorgenszternWashington University School of Medicine
  • 1 - 4

Datasets

Release 1.2